Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02663518 · OUTCOME

Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors · Source last updated 2024-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)

What was measured

ORR is presented in this outcome measure as number of responders. Responders were those who had complete response and partial response. Clinical endpoints and response criteria (Olsen et al., 2011) for in CTCL (mycosis fungoides and Sezary syndrome) and TCL were used for assessment. Tumor types evaluated included Cutaneous T-cell lymphoma (CTCL) and a part of T-cell lymphoma (TCL).

Analysis population: Full analysis set included all participants who received at least 1 dose of study treatment. "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.

Groups in this outcome

Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL)

Participants with CTCL who received study drug in Parts 2 and 3.

Parts 2 and 3: T-cell Lymphoma (TCL)

Participants with TCL who received study drug and response assessment by Olsen 2011 in Parts 2 and 3.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL)21
Parts 2 and 3: T-cell Lymphoma (TCL)29

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL)2Not reportedNot reportedNot reportedNot reported
Parts 2 and 3: T-cell Lymphoma (TCL)5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    2. group Id
      OG001
      value
      29
    units
    Participants
description
ORR is presented in this outcome measure as number of responders. Responders were those who had complete response and partial response. Clinical endpoints and response criteria (Olsen et al., 2011) for in CTCL (mycosis fungoides and Sezary syndrome) and TCL were used for assessment. Tumor types evaluated included Cutaneous T-cell lymphoma (CTCL) and a part of T-cell lymphoma (TCL).
groups
  1. description
    Participants with CTCL who received study drug in Parts 2 and 3.
    id
    OG000
    title
    Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL)
  2. description
    Participants with TCL who received study drug and response assessment by Olsen 2011 in Parts 2 and 3.
    id
    OG001
    title
    Parts 2 and 3: T-cell Lymphoma (TCL)
param Type
COUNT_OF_PARTICIPANTS
population Description
Full analysis set included all participants who received at least 1 dose of study treatment. "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.
reporting Status
POSTED
time Frame
From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
title
Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice